You have read all your free articles, to continue reading subscribe to read the rest of this content.
LINK Medical and Ectin Research have signed an agreement appointing LINK Medical Research to run the Phase I/II clinical study of the treatment of metastatic bladder cancer patients with the drug candidate MFA-370. Ectin Research aims to submit its clinical trial application (CTA) to the Swedish Already a subscriber Login…
Ultimovacs has announced that the first patient has been enrolled in FOCUS. FOCUS is an investigator-led Phase II randomized clinical trial in head-and-neck cancer of the company’s telomerase cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab. “Initiation of reAlready a subscriber Login You have read all your free…
Genmab and Seattle Genetics has presented data from the innovaTV 204 phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer. Patients had previously received a doublet chemotherapy and, if eligAlready a subscriber Login You have read all your free…
Genmab A/S announces that its collaboration partner Novartis will start Phase III studies of the subcutaneous formulation of ofatumumab in relapsing multiple sclerosis (MS) with enrolment of patients expected to start in September 2016. The studies will compare the efficacy and safety of subcutanAlready a subscriber Login You have read…
